Abstract 1985: Ipilimumab and nivolumab induced reactivation of hepatitis B (HBVr) in patient with metastatic squamous cell lung cancer

Background: Unique adverse events caused by immunological perturbation of immune checkpoint inhibitor (ICI) treatment were reported. Recently, it came into light that ICI can increase the risk of HBVr. Immune-mediated adverse events including immune-mediated hepatitis have been widely reported. Howe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2022-06, Vol.82 (12_Supplement), p.1985-1985
Hauptverfasser: Kim, Leeseul, Choi, Horyun, Lee, Yeun Ho, Kim, Jinah, Chae, Young Kwang
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Unique adverse events caused by immunological perturbation of immune checkpoint inhibitor (ICI) treatment were reported. Recently, it came into light that ICI can increase the risk of HBVr. Immune-mediated adverse events including immune-mediated hepatitis have been widely reported. However, HBVr is an extremely rare adverse event that has been seldom reported. Herein, we report the first case of ipilimumab/nivolumab induced HBVr in metastatic squamous cell lung cancer patient. Case Presentation: 71-year-old Asian gentlemen with stage IIIB poorly differentiated squamous cell carcinoma of the lung (PD-L1 immunohistochemistry 5-10%) was initially treated with 4 cycles of carboplatin/paclitaxel/pembrolizumab and one dose of maintenance pembrolizumab. The treatment was complicated by immune-related adverse events of thyroiditis and adrenal insufficiency and followed by surgical resection of the tumor. Unfortunately, he developed recurrent metastatic disease of the brain which provoked craniotomy and resection followed by multiple courses of radiation therapy. The patient was then started on treatment with ipilimumab/nivolumab maintenance therapy following 2 cycles of carboplatin/paclitaxel/nivolumab/ipilimumab combined therapy (every 3 weeks). Bevacizumab was added for cerebral edema associated with brain metastasis. The patient was initially noted to be positive for hepatitis B Antigen. However, he was asymptomatic and liver function test (LFT) and liver ultrasound were unremarkable. He had been monitored for LFT at every visit. After 5.5 months from starting the treatment (after seven cycles of ipilimumab/nivolumab and six cycles of bevacizumab), transaminitis was noted and treatment was held. He was admitted for abdominal pain with labs demonstrating hepatocellular injury with ALT 1761 units/L, AST 607 units/L, and total bilirubin 3.3 mg/dL. Hepatitis work-up revealed HBVr (positive for HBs Ag, hepatitis B viral load 11,745). Patient was started on tenofovir daily and LFT was normalized after three weeks without synthetic dysfunction or metabolic encephalopathy. Ipilimumab/nivolumab treatment was held for six weeks and reintroduced without any further significant events. Conclusion: It has recently been reported that pembrolizumab had a strong signal associated with HBVr. However, to our knowledge, this is the first case report for HBVr in squamous cell carcinoma of lung patient treated with ipilimumab/nivolumab. ASCO recommends universal screen
ISSN:1538-7445
1538-7445
DOI:10.1158/1538-7445.AM2022-1985